TouchNEUROLOGY recently spoke with Jeffrey Cummings (Department of Brain Health, University of Nevada, Las Vegas, US), one of its Editorial Board members, to discuss the use of BAN2401 in early stage Alzheimer’s disease (AD), and Amyloid Related Imaging Abnormalities (ARIA)-E alterations and their utility in amyloid-modifying trials. The interview was filmed at the American Academy of Neurology Virtual Annual Meeting 2021, held online between 17 and 22 April 2021, and was published online on 23 April 2021. You can watch it, here: